Pearl Fang, PhD

Vice President, Clinical Development, Clinical Research Operations

Dr. Fang has over 16 years of experience in the biopharmaceutical industry across the spectrum of early drug development and through the commercialization process.  This includes roles in the pre-approval and post-approval setting in clinical science and pharmacology, as well as medical and scientific affairs in hematology/oncology/immuno-oncology.  Most recently, Dr. Fang was a Senior Director of Clinical Research and Development at ARMO Biosciences where she was responsible for the clinical development of pegilodecakin (pegylated human interleukin-10) and AM-0001 (anti-PD-1 checkpoint inhibitor).  Previously, she worked at Puma Biotechnology, Amgen, Inc., Onyx, Inc., Cephalon, and Eli Lilly and Company where she launched several oncologic therapies.  Dr. Fang graduated from the University of Southern California (USC) with her B.A., M.A. and Ph.D. in Clinical Neuroscience.